Cardiol Therapeutics
CRDL
41 hedge funds and large institutions have $8.69M invested in Cardiol Therapeutics in 2025 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 11 increasing their positions, 12 reducing their positions, and 14 closing their positions.
11% more capital invested
Capital invested by funds: $7.8M → $8.69M (+$884K)
0.66% more ownership
Funds ownership: 8.49% → 9.15% (+0.66%)
8% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 12
15% less funds holding
Funds holding: 48 → 41 (-7)
36% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TC
Tejara Capital
London,
United Kingdom
|
+$2.62M |
| 2 |
IA
Integrity Alliance
Urbandale,
Iowa
|
+$456K |
| 3 |
Morgan Stanley
New York
|
+$197K |
| 4 |
Two Sigma Investments
New York
|
+$183K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$116K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$485K |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$411K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$192K |
| 4 |
VF
Virtu Financial
New York
|
-$154K |
| 5 |
MI
MMCAP International
Grand Cayman,
Cayman Islands
|
-$88.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PFG
51
Prosperity Financial Group
San Ramon,
California
| – | -$5.35K | -5,000 | Closed |
|
52
Group One Trading
Chicago,
Illinois
| – | -$1.61K | -1,534 | Closed |
|
|
SC
53
SouthState Corp
Winter Haven,
Florida
| – | -$1.07K | -1,000 | Closed |
|
|
RFP
54
Root Financial Partners
Encinitas,
California
| – | -$535 | -500 | Closed |
|
|
PPA
55
Painted Porch Advisors
Santa Barbara,
California
| – | -$157 | -147 | Closed |
|
CRDL Hedge Fund Activity: Q4 2025 in Review
41 of the 8,225 institutional investors tracked by Wall St. Rank reported a position in Cardiol Therapeutics (CRDL) for Q4 2025, worth a combined $8.69M — up 11% from $7.8M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of CRDL and 9 opened new positions — a net loss of 5 holders — while 12 trimmed existing stakes and 11 added.
The largest buyer was Tejara Capital, adding an estimated $2.62M. The largest seller was Citadel Advisors, exiting entirely with an estimated $485K sold.
- 41 institutional investors held Cardiol Therapeutics (CRDL) as of Q4 2025, down from 48 in Q3 2025.
- Funds reported $8.69M of Cardiol Therapeutics stock for Q4 2025, up 11% quarter-over-quarter.
- 9 funds opened new Cardiol Therapeutics positions in Q4 2025 and 14 closed out, a net change of -5 holders.
- The largest Cardiol Therapeutics buyer in Q4 2025 was Tejara Capital, an estimated $2.62M added.
- The largest Cardiol Therapeutics seller in Q4 2025 was Citadel Advisors, an estimated $485K sold.
Based on aggregated 13F filings for Q4 2025.